The European Hematology Association (EHA)

The European Hematology Association (EHA) is a non-governmental and not-for-profit membership organization that is guided by its mission to promote excellence in patient care, research, and education in hematology.

Isatuximab plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients with Gain(1q21)

EHA 2020 – Multiple Myeloma

A retrospective analysis of ICARIA-MM and TCD14079 studies shows adding isatuximab to pomalidomide-dexamethasone improved progression-free survival and increased rates of overall response and very good partial response or better in patients with gain(1q21). Read More ›

Bortezomib, Lenalidomide, and Dexamethasone with or without Elotuzumab for Newly Diagnosed Multiple Myeloma

EHA 2020 – Multiple Myeloma

Adding elotuzumab to bortezomib/lenalidomide/dexamethasone as induction therapy for newly diagnosed multiple myeloma patients in the GMMG-HD6 study failed to increase the rates of very good partial response and complete response after 4 cycles. Read More ›

Pomalidomide, Cyclophosphamide, and Dexamethasone (POMCIDEX) in Relapsed/Refractory Multiple Myeloma

EHA 2020 – Multiple Myeloma

Pragmatic setting administration of the all-oral combination of pomalidomide plus cyclophosphamide/dexamethasone (POMCIDEX) is a manageable, effective treatment option for patients with relapsed/refractory multiple myeloma. Read More ›

Comparison of MRD Status by 3 Techniques in Newly Diagnosed Transplant-Eligible MM Patients

EHA 2020 – Multiple Myeloma

In newly diagnosed transplant-eligible multiple myeloma patients who achieved very good partial response or better in the Italian FORTE study, there was strong concordance among 3 minimal residual disease–assessing techniques. Read More ›

Ixazomib Maintenance Therapy in NDMM Patients Not Treated with Stem-Cell Transplantation

EHA 2020 – Multiple Myeloma

Post-induction ixazomib as maintenance therapy in patients newly diagnosed with multiple myeloma not treated with front-line stem-cell transplantation (TOURMALINE-MM4 trial) resulted in median progression-free survival of 17.4 months with tolerable safety. Read More ›

GMMG-Concept Trial: Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone in Treatment of High-Risk Multiple Myeloma

EHA 2020 – Multiple Myeloma

In the GMMG-Concept trial, the addition of isatuximab to carfilzomib/lenalidomide/ dexamethasone in newly diagnosed high-risk patients with multiple myeloma led to an approximately 90% rate of very good partial response or better with manageable toxicity. Read More ›

Subgroup Analysis of Carfilzomib and Dexamethasone with or without Daratumumab in RRMM

EHA 2020 – Multiple Myeloma

Efficacy and toxicity outcome measures with daratumumab added to carfilzomib/dexamethasone were consistent across subgroups within the CANDOR trial, regardless of lenalidomide- or bortezomib-refractory status or number of previous treatments. Read More ›

Idecabtagene Vicleucel, a BCMA-Targeted CAR T-Cell Therapy, in Patients with RRMM

EHA 2020 – Multiple Myeloma

Idecabtagene vicleucel resulted in an overall response rate of 73% and demonstrated a tolerable safety profile in heavily pretreated patients who were refractory to their last regimen in the KarMMa trial. Read More ›

Literature Review to Assess Options for RRMM Patients with Triple-Class Exposure Indicates Urgent Need for New Treatments

EHA 2020 – Multiple Myeloma

A systematic literature review to investigate evidence for therapies in patients with RRMM suggests there is limited published efficacy data available to support treatment options for heavily pretreated patients with RRMM. Read More ›

Isatuximab plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

EHA 2020 – Multiple Myeloma

Isatuximab plus carfilzomib/dexamethasone (IKEMA study) shows promising efficacy and tolerable safety in prolonging progression-free survival compared with carfilzomib/dexamethasone alone in the treatment of patients with RRMM. Read More ›

The European Hematology Association (EHA)

Page 2 of 5